Stocktoria
enGene Therapeutics Inc. ENGN
enGene Therapeutics Inc. (ENGN) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.765 |
| Retained earnings / assets | -1.68 |
| EBIT / assets | -0.556 |
| Equity / liabilities | 3.12 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | 1/9 | -0.92 | — | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
About enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
FAQ
Is ENGN financially healthy?
enGene Therapeutics Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ENGN pay a dividend?
No, enGene Therapeutics Inc. does not currently pay a dividend.
How profitable is ENGN?
In FY2025, enGene Therapeutics Inc. had a return on equity of -69.9%.
Is ENGN overvalued or undervalued?
enGene Therapeutics Inc. trades at about 0.9× trailing earnings — below its 10-year norm (10-year range 0.1×–5.9×, median 3.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ENGN?
The average Wall-Street price target for enGene Therapeutics Inc. is $3.29, about 67.6% above the recent price, from 7 analysts (consensus: hold).
Is ENGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on enGene Therapeutics Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-10-31. Facts plus Stocktoria's own computed scores — not investment advice.